Author(s) :

Tanmayee Vegunta.

Volume/Issue :

Abstract :

The management and treatment of colorectal cancer (CRC) has recently focused on two new and upcoming therapies: Chimeric Antigen Receptor T-cells(CAR-T cells) and nanoparticles. CAR-T Cells are T cells that have been genetically modified to detect and target cancer cells in the body by delivering medication into the body in the area where the cancer cells are present. Nanoparticles are microscopic particles engineered to detect and target cancer cells in the body by delivering medication or staining lymph nodes in a combined therapy approach. This paper addresses the question of how CAR-T cell therapies and nanoparticles can be used as a treatment for CRC, acknowledging the limitations and consequences present. Analysis of CAR-T cells has shown promising results in terms of medication administration and the prevention of metastases. Analysis of nanoparticles has shown promising results in the detection of sentinel lymph nodes(SLN) and the administration of medication. Both treatments show measurable effects, but this is not without the presence of different adverse effects that highlight the need for further analysis and additional supportive measures through combination therapies.